Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Ongoing Trials Poster Session Abstracts

Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer

A Lluch-Hernández, A Ruiz Simon, C-S Huang, J Cortés Castán, M Ruiz-Borrego, M Telli, R Ismail-Khan, M Parton, L-M Tseng, S-C Chen, P Schmid, I Mayer, S Hurvitz, L García-Estévez, R Atienza, M Wu, S Cameron, JT Beck and A Bardia
A Lluch-Hernández
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Ruiz Simon
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C-S Huang
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Cortés Castán
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Ruiz-Borrego
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Telli
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Ismail-Khan
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Parton
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L-M Tseng
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S-C Chen
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Schmid
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I Mayer
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Hurvitz
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L García-Estévez
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Atienza
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Wu
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Cameron
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JT Beck
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Bardia
Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.SABCS13-OT1-4-04 Published December 2013
  • Article
  • Info & Metrics
Loading
Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX

Abstract

Background: Inhibitor of apoptosis proteins (IAPs) negatively regulate cell death through a variety of mechanisms. LCL161 is an oral small-molecule antagonist of IAPs that has demonstrated single-agent activity and synergy with paclitaxel in breast cancer tumor models. In preclinical studies, a gene expression signature has been shown to enrich for response to LCL161. The recommended dose of LCL161 1800 mg once weekly has demonstrated preliminary antitumor activity with paclitaxel in an ongoing Phase Ib study in patients with breast cancer.

Trial design: This is a Phase II, randomized, open-label study of neoadjuvant paclitaxel with or without LCL161 in women with operable, newly diagnosed triple-negative breast cancer (NCT01617668). Key inclusion criteria include women with histologically confirmed diagnosis of triple-negative breast cancer; clinical stages T2, N0–N2, M0; candidates for mastectomy or breast-conserving surgery; ECOG performance status ≤1; known status of the LCL161-predictive gene expression signature (positive and negative gene signature is a stratification factor); and adequate bone marrow and organ function. Key exclusion criteria are: bilateral or inflammatory breast cancer; locally recurrent breast cancer; patients currently receiving systemic therapy for any other malignancy, or having received systemic therapy for a malignancy in the preceding 3 months; impaired gastrointestinal function that may affect the absorption of LCL161; or uncontrolled cardiac disease.

Patients are randomized 1:1 to receive paclitaxel IV (80 mg/m2 weekly) with or without oral LCL161 (1800 mg once weekly) for 12 weeks (corresponding to 4 treatment cycles). Each treatment arm is stratified 1:1 based on gene expression signature status (positive or negative).

Endpoints: The primary endpoint is pathologic complete response (pCR), defined as the absence of invasive disease in the breast after 12 weeks of therapy, analyzed separately in the gene expression signature positive and negative groups. The key secondary endpoint is the pCR rate following treatment with LCL161 and paclitaxel in gene expression signature-positive or -negative tumors. Other secondary endpoints include: pCR rate in breast after 12 weeks of therapy in the full study population, and in patients with gene expression signature-positive and -negative tumors treated with paclitaxel alone; pCR rate in breast, regional nodes and axilla; biomarker evaluation including caspase 3 activation in tumor; safety; and pharmacokinetics of LCL161.

Statistical methods: pCR analysis will be performed according to treatment group and gene expression signature status. An absolute increase of at least 7.5% in pCR rate of the experimental arm over the control arm will be considered as evidence of clinically relevant efficacy.

Target accrual: Approximately 200 patients will be randomized into this study. Recruitment is ongoing across America, Europe, and Asia.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT1-4-04.

Previous
Back to top
Cancer Research: 73 (24 Supplement)
December 2013
Volume 73, Issue 24 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer
A Lluch-Hernández, A Ruiz Simon, C-S Huang, J Cortés Castán, M Ruiz-Borrego, M Telli, R Ismail-Khan, M Parton, L-M Tseng, S-C Chen, P Schmid, I Mayer, S Hurvitz, L García-Estévez, R Atienza, M Wu, S Cameron, JT Beck and A Bardia
Cancer Res December 15 2013 (73) (24 Supplement) OT1-4-04; DOI: 10.1158/0008-5472.SABCS13-OT1-4-04

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer
A Lluch-Hernández, A Ruiz Simon, C-S Huang, J Cortés Castán, M Ruiz-Borrego, M Telli, R Ismail-Khan, M Parton, L-M Tseng, S-C Chen, P Schmid, I Mayer, S Hurvitz, L García-Estévez, R Atienza, M Wu, S Cameron, JT Beck and A Bardia
Cancer Res December 15 2013 (73) (24 Supplement) OT1-4-04; DOI: 10.1158/0008-5472.SABCS13-OT1-4-04
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Ongoing Trials Poster Session Abstracts

  • Abstract OT2-3-04: A PILOT PHASE II STUDY TO EVALUATE THE IMPACT OF DENOSUMAB ON DISSEMINATED TUMOR CELLS (DTC) IN PATIENTS WITH EARLY STAGE BREAST CANCER (ESBC)
  • Abstract OT3-4-04: InVite: an observational pilot study evaluating the feasibility of genome-wide association studies using self-reported data from patients with metastatic breast cancer treated with bevacizumab
  • Abstract OT3-3-01: Eniluracil + 5-fluorouracil + leucovorin (EFL) vs. capecitabine phase 2 trial for metastatic breast cancer
Show more 3

Ongoing Clinical Trials 1: New Agents

  • Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC)
  • Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC)
  • Abstract OT1-4-05: Phase I dose-escalation study of oral administration of abexinostat (S 78454, PCI-24781) given with tamoxifen 20 mg in the treatment of patients with advanced breast cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement